Blue Note Therapeutics

Recent Finacing

Series A ext

Recent Raise

$5.2M

Blue Note Therapeutics develops prescription digital therapeutics for cancer-related anxiety, depression, and distress, partnering with cancer centers to digitize evidence-based therapies; lead product BNT001 has FDA Breakthrough Device status.

Founded 2018

California, United States

11-50

Private

bluenotetherapeutics.com

Highlights

Focus Areas

Health Care

Health Diagnostics

Medical

Therapeutics

Recent Investors

S

Financials

$31.4M

Total Raised

2

Funding rounds

4

Investors

Team

Upgrade to view the team

See the team members at Blue Note Therapeutics.